v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Revenues $ 810.9 $ 776.0
Operating expenses:    
Salaries and benefits 247.4 238.6
Supplies 220.2 215.8
Professional and medical fees 101.3 95.3
Lease expense 23.0 20.8
Other operating expenses 58.8 43.6
Cost of revenues 650.7 614.1
General and administrative expenses 39.3 36.0
Depreciation and amortization 38.5 36.3
Transaction and integration costs 15.6 24.7
Net loss on disposals, consolidations and deconsolidations 4.3 6.4
Equity in earnings of unconsolidated affiliates (4.1) (5.6)
Litigation settlements 2.5 2.2
Other income, net (1.7) 0.0
Total operating expenses 745.1 714.1
Operating income 65.8 61.9
Interest expense, net (69.1) (62.2)
Income (loss) before income taxes (3.3) (0.3)
Income tax (expense) benefit 1.2 0.0
Net income (loss) (2.1) (0.3)
Less: Net income attributable to non-controlling interests (33.8) (37.4)
Net income (loss) attributable to Surgery Partners, Inc. $ (35.9) $ (37.7)
Net loss per share attributable to common stockholders:    
Basic (in USD per share) $ (0.28) $ (0.30)
Diluted (in USD per share) [1] $ (0.28) $ (0.30)
Weighted average common shares outstanding:    
Basic (shares) 128,367 126,602
Diluted (shares) [1] 128,367 126,602
[1] The impact of potentially dilutive securities for all periods was not considered because the effect would be anti-dilutive.